AstraZeneca announced on Feb. 5, 2015 that it had entered into a definitive agreement with Actavis to acquire the rights to Actavis branded respiratory business in the US and Canada for an initial consideration of $600 million upon acquisition completion and low single-digit royalties aOriginal Article
You may also like
New alloys for manufacturing freeze-dryers
Navigating the Complexities of Emerging Therapy...
INTERPHEX 2025: Preventing Spills in the Manufacturing...
Agentic AI Growth Predicted, but More Than Half of...
Microsoft and SkyCell Collaborate on Pharma Supply...
Siemens Acquires Dotmatics, Extending AI Software...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.